Vistagen Therapeutics, Inc. Announces Company-Wide Stock Option Grants to Executives and Employees

South San Francisco, CA – April 13, 2026 – Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a clinical-stage biopharmaceutical company, has announced significant developments regarding executive compensation that may be of interest to shareholders and could have implications for the company’s stock price.

Key Highlights

• Retention Stock Option Grants Approved: On April 7, 2026, the Compensation Committee of Vistagen’s Board of Directors, in consultation with an independent compensation consultant, approved a company-wide retention award in the form of stock option grants. These options are being granted to all company employees, including the company’s executive leadership team.
• Executive Recipients and Details: The following top executives each received options to purchase up to 75,000 shares of Vistagen’s common stock, at an exercise price of \$0.5358 per share:
  • Shawn K. Singh, President and Chief Executive Officer
  • Reid G. Adler, Chief Legal Officer
  • Elissa S. Cote, Chief Corporate Development Officer
  • Joshua S. Prince, Chief Operating Officer
  • Nick B. Tressler, Chief Financial Officer
• Vesting Schedule: The options were granted under the Company’s Amended and Restated 2019 Omnibus Equity Incentive Plan. The vesting schedule is as follows:
  • 25% of the options vest six months after the grant date (April 7, 2026).
  • The remaining 75% vest in equal 25% tranches every six months thereafter, resulting in full vesting on the two-year anniversary of the grant date.
• Additional Information: The company states that the summary is not exhaustive and that the final terms are subject to the 2019 Plan and the applicable award agreements.

Potential Shareholder Impact

• Retention and Alignment: The issuance of stock options to all employees, particularly to the executive team, is designed to incentivize retention and align management interests with those of shareholders. Such measures are often implemented to motivate the team to drive company performance and share price appreciation.
• Possible Dilution: While option grants can be a strong motivational tool, they may also result in shareholder dilution if and when exercised, as they increase the number of shares outstanding.
• Price Sensitivity: The grant price of \$0.5358 per share provides a clear benchmark for management motivation. Should the company’s stock price rise above this level, executives and employees stand to benefit directly, which may incentivize actions to enhance shareholder value. However, the market may also interpret increased option grants as a signal of management’s need to secure retention, which could be a two-edged sword depending on overall business performance.
• No Indication of Immediate Business Events: The filing does not announce any changes in company leadership, departures, or new appointments beyond the option grants. Nor does it refer to new business developments, partnerships, or clinical results that might otherwise drive the share price in the short term.

Corporate Information

• Company Name: Vistagen Therapeutics, Inc.
• Trading Symbol: VTGN
• Exchange: Nasdaq Capital Market
• Business Address: 343 Allerton Avenue, South San Francisco, CA 94080
• Phone: 650-577-3600
• State of Incorporation: Nevada (NV)
• Fiscal Year End: March 31

Conclusion

The approval and issuance of new stock options to Vistagen’s executives and all employees is a noteworthy event for shareholders. It signals the company’s commitment to retaining its leadership team and employees and aligning their interests with those of shareholders. Investors should be aware of the potential for future dilution and consider the implications of this move in the context of the company’s overall performance and pipeline developments. No other material corporate events or financial results were disclosed in this filing.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult with a financial advisor before making investment decisions. The information presented is based on public filings and may not reflect the most current developments at Vistagen Therapeutics, Inc.

View Vistagen Therapeutics, Inc. Historical chart here